19.36
price down icon0.31%   -0.06
 
loading
Genmab Adr stock is traded at $19.36, with a volume of 2.19M. It is down -0.31% in the last 24 hours and up +2.81% over the past month. Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
See More
Previous Close:
$19.42
Open:
$19.61
24h Volume:
2.19M
Relative Volume:
1.51
Market Cap:
$13.36B
Revenue:
$2.89B
Net Income/Loss:
$684.26M
P/E Ratio:
18.40
EPS:
1.0524
Net Cash Flow:
$958.82M
1W Performance:
-9.87%
1M Performance:
+2.81%
6M Performance:
-16.12%
1Y Performance:
-32.80%
1-Day Range:
Value
$19.35
$19.96
1-Week Range:
Value
$19.35
$21.76
52-Week Range:
Value
$17.23
$30.41

Genmab Adr Stock (GMAB) Company Profile

Name
Name
Genmab Adr
Name
Phone
-
Name
Address
-
Name
Employee
2,682
Name
Twitter
@Genmab
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
GMAB's Discussions on Twitter

Compare GMAB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
GMAB
Genmab Adr
19.36 13.36B 2.89B 684.26M 958.82M 1.0524
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
424.99 128.84B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
527.78 65.38B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
549.65 39.67B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.15 33.82B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
231.99 27.60B 3.81B -644.79M -669.77M -6.24

Genmab Adr Stock (GMAB) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-01-25 Downgrade Bernstein Mkt Perform → Underperform
Mar-11-25 Upgrade William Blair Mkt Perform → Outperform
Feb-13-25 Upgrade Leerink Partners Market Perform → Outperform
Oct-08-24 Initiated Redburn Atlantic Buy
Sep-04-24 Resumed Morgan Stanley Equal-Weight
Aug-20-24 Downgrade JP Morgan Overweight → Neutral
Jul-15-24 Upgrade RBC Capital Mkts Sector Perform → Outperform
Feb-23-24 Upgrade BMO Capital Markets Market Perform → Outperform
Jan-22-24 Downgrade Citigroup Neutral → Sell
Dec-06-23 Upgrade UBS Neutral → Buy
Nov-10-23 Upgrade Deutsche Bank Hold → Buy
Nov-08-23 Upgrade DNB Markets Sell → Buy
Oct-18-23 Initiated Exane BNP Paribas Underperform
Sep-06-23 Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-24-23 Initiated BTIG Research Buy
Jul-14-23 Initiated HSBC Securities Buy
May-31-23 Initiated UBS Neutral
May-12-23 Initiated Morgan Stanley Underweight
Dec-20-22 Downgrade Citigroup Buy → Neutral
Nov-14-22 Initiated William Blair Mkt Perform
Nov-11-22 Downgrade Deutsche Bank Buy → Hold
Jun-24-22 Initiated BMO Capital Markets Market Perform
May-02-22 Initiated Cowen Market Perform
Mar-16-22 Upgrade UBS Neutral → Buy
Jan-31-22 Upgrade H.C. Wainwright Neutral → Buy
Jan-03-22 Downgrade Guggenheim Buy → Neutral
Dec-01-21 Initiated Berenberg Sell
Sep-16-21 Downgrade Jefferies Buy → Hold
Sep-07-21 Downgrade Morgan Stanley Equal-Weight → Underweight
Aug-24-21 Downgrade H.C. Wainwright Buy → Neutral
Apr-20-21 Initiated Deutsche Bank Buy
Jan-19-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-23-20 Downgrade Bryan Garnier Neutral → Sell
Sep-08-20 Initiated SVB Leerink Mkt Perform
Jun-25-20 Downgrade Credit Suisse Outperform → Neutral
Apr-23-20 Initiated Credit Suisse Outperform
Feb-24-20 Reiterated H.C. Wainwright Buy
Jan-13-20 Initiated SunTrust Buy
Dec-12-19 Downgrade Deutsche Bank Buy → Hold
Sep-13-19 Upgrade BofA/Merrill Neutral → Buy
Sep-12-19 Upgrade JP Morgan Neutral → Overweight
Aug-12-19 Initiated Guggenheim Buy
Aug-12-19 Initiated Morgan Stanley Overweight
Aug-12-19 Initiated RBC Capital Mkts Outperform
View All

Genmab Adr Stock (GMAB) Latest News

pulisher
May 09, 2025

Applied Dna Sciences Inc (APDN)’s Day in Review: Closing at 0.85, Down by -2.41 - DWinneX

May 09, 2025
pulisher
May 09, 2025

Stock Surge: Genmab ADR (GMAB) Closes at 19.42, Marking a -5.73 Increase/Decrease - DWinneX

May 09, 2025
pulisher
May 09, 2025

Market Momentum Report: Evercore Inc (EVR)’s Positive Close at 216.74 - DWinneX

May 09, 2025
pulisher
May 01, 2025

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) - GlobeNewswire Inc.

May 01, 2025
pulisher
Apr 23, 2025

Investing in Take-Two Interactive Software, Inc (TTWO) Is Getting More Attractive - knoxdaily.com

Apr 23, 2025
pulisher
Apr 23, 2025

Investing in Genmab ADR (GMAB): What You Must Know - knoxdaily.com

Apr 23, 2025
pulisher
Apr 23, 2025

Nucor Corp (NUE) may enjoy gains as insiders got busy in the recent days - knoxdaily.com

Apr 23, 2025
pulisher
Apr 21, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Apr 21, 2025
pulisher
Apr 17, 2025

EWTX Stock Sees Surge of Approximately 4.24% in Last Five Days - knoxdaily.com

Apr 17, 2025
pulisher
Apr 16, 2025

GMAB or RGEN: Which Is the Better Value Stock Right Now? - Yahoo Finance

Apr 16, 2025
pulisher
Apr 16, 2025

Should Value Investors Buy Genmab (GMAB) Stock? - Yahoo Finance

Apr 16, 2025
pulisher
Apr 15, 2025

Genmab ADR (NASDAQ: GMAB) Jumps 1.19% In Recent Session. Here’s Everything You Need To Know. - Stocksregister

Apr 15, 2025
pulisher
Apr 10, 2025

AGCO Corp (AGCO) Beta Value: Understanding the Market Risk - News Heater

Apr 10, 2025
pulisher
Apr 04, 2025

Evercore Inc’s Mixed Bag: Down -29.24% in 6 Months, Down -20.22% in 30 Days - investchronicle.com

Apr 04, 2025
pulisher
Apr 04, 2025

GMAB’s Debt-to-Equity Ratio at 0.03: What It Means for Genmab ADR’s Future - investchronicle.com

Apr 04, 2025
pulisher
Apr 03, 2025

CZR Stock Sees Decline of Approximately -4.82% in Last Five Days - knoxdaily.com

Apr 03, 2025
pulisher
Mar 31, 2025

Magnite Inc (MGNI) may enjoy gains as insiders got busy in the recent days - knoxdaily.com

Mar 31, 2025
pulisher
Mar 26, 2025

DLocal Limited (DLO) Shares Decline Despite Market Challenges - The News Heater

Mar 26, 2025
pulisher
Mar 12, 2025

Genmab ADR Inc. (GMAB) Price Performance: The Role of Supply and Demand - The InvestChronicle

Mar 12, 2025
pulisher
Feb 07, 2025

Views of Wall Street’s Leading Experts on Genmab ADR - SETE News

Feb 07, 2025
pulisher
Feb 07, 2025

What is Core & Main Inc (CNM) Stock Return on Shareholders’ Capital? - SETE News

Feb 07, 2025
pulisher
Feb 07, 2025

There is no doubt that Kite Realty Group Trust (KRG) ticks all the boxes. - SETE News

Feb 07, 2025
pulisher
Jan 29, 2025

Sea Ltd ADR (NYSE: SE) Jumps 4.64%, Turning Investors Away - Stocks Register

Jan 29, 2025
pulisher
Jan 29, 2025

Does Genmab ADR (NASDAQ: GMAB) Still Look Hot This Week? - Stocks Register

Jan 29, 2025
pulisher
Jan 20, 2025

Genmab (GMAB) Upgraded to Buy: Here's What You Should Know - MSN

Jan 20, 2025
pulisher
Jan 17, 2025

GMAB vs. QGEN: Which Stock Is the Better Value Option? - MSN

Jan 17, 2025
pulisher
Jan 14, 2025

Are Investors Undervaluing Genmab (GMAB) Right Now? - Yahoo Finance

Jan 14, 2025
pulisher
Jan 08, 2025

Genmab stock holds Buy rating on positive trial results - Investing.com

Jan 08, 2025
pulisher
Nov 18, 2024

10 Biggest Biotechnology Companies - Investopedia

Nov 18, 2024
pulisher
Nov 12, 2024

Weekly Upgrades and Downgrades - InvestorPlace

Nov 12, 2024
pulisher
Oct 16, 2024

Is the Options Market Predicting a Spike in Genmab (GMAB) Stock? - Yahoo Finance

Oct 16, 2024
pulisher
Oct 15, 2024

Is Genmab (GMAB) Stock Undervalued Right Now? - Yahoo Finance

Oct 15, 2024
pulisher
Oct 08, 2024

Down -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a Turnaround - Yahoo Finance

Oct 08, 2024
pulisher
Aug 05, 2024

BioNTech's Loss Quadruples as COVID-19 Vaccine Demand Falls - Yahoo Finance

Aug 05, 2024
pulisher
Jul 15, 2024

RBC Capital upgrades Genmab stock amid strong pipeline prospects - Investing.com

Jul 15, 2024
pulisher
Jun 27, 2024

FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma - Yahoo Finance

Jun 27, 2024
pulisher
Apr 03, 2024

Genmab's 'Evolution' Continues With A $1.8 Billion Deal; But Shares Slip - Investor's Business Daily

Apr 03, 2024
pulisher
Mar 01, 2024

GMAB: Bank on the Future Returns With These 3 Biotech Stocks - StockNews

Mar 01, 2024
pulisher
Sep 05, 2023

Zai Lab ADR surges after Seagen, Genmab release cervical cancer treatment results - MarketWatch

Sep 05, 2023
pulisher
Apr 13, 2023

Genmab ADR Getting Closer To Key Technical Measure - Investor's Business Daily

Apr 13, 2023
pulisher
Feb 23, 2023

Stocks Flashing Renewed Technical Strength: Ascendis Pharma ADR - Investor's Business Daily

Feb 23, 2023
pulisher
Jan 23, 2023

GILD or GMAB: Which Is the Better Value Stock Right Now? - Yahoo News Canada

Jan 23, 2023
pulisher
Jan 11, 2023

New Strong Buy Stocks for January 11th - Yahoo Finance

Jan 11, 2023
pulisher
Dec 12, 2022

Is Elevance Health, Inc. (ELV) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Dec 12, 2022
pulisher
Dec 02, 2022

Oncolytics Biotech Inc. (ONCY) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance

Dec 02, 2022
pulisher
Nov 17, 2022

Genmab AS Sponsored ADR (GMAB) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance

Nov 17, 2022

Genmab Adr Stock (GMAB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$65.08
price down icon 0.84%
$33.15
price up icon 0.15%
$23.96
price down icon 2.80%
$92.77
price down icon 2.12%
biotechnology ONC
$231.99
price down icon 1.67%
Cap:     |  Volume (24h):